ArticleScientific reports2025
IL-22 attenuates MAFLD progression by modulating oxidative stress and ferroptosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metabolic-associated fatty liver disease (MAFLD) is a common liver disease in clinical practice and currently has limited standardized medications or treatments. The study aimed to evaluate the therapeutic effects of interleukin-22 (IL-22) on metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, and to explore its underlying molecular mechanisms. Male C57BL/6J mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for 12 weeks and treated with different doses of IL-22 intraperitoneally. IL-22 treatment significantly reduced hepatic lipid accumulation, suppressed hepatic stellate cell (HSC) activation, and prevented liver fibrosis. It also attenuated oxidative stress, evidenced by elevated SOD levels and reduced ROS, MDA levels. Meanwhile, changes in mitochondria morphology, along with alterations in GSH and Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.